Patrick Campbell

An analysis of 7 international, longitudinal studies with nearly 20,000 patients details apparent increases in risk associated with daily alcohol consumption among healthy adults.

Using NHANES data, along with deidentified data from the Optum database, investigators estimate the prevalence of albuminuria testing among people with hypertension or diabetes as well as how the presence or lack of testing might influence prescription of CKD therapies.

The FDA has announced Abiomed has initiated a recall of all left-sided Impella pumps, citing inadequate instructions for use as it pertains to precautions to take with patients who have undergone TAVR.

On July 27, 2023, Eli Lilly and Company announced topline results of the SURMOUNT-3 and SURMOUNT-4 trials, with both trials achieving all primary endpoints of interest and full results scheduled to be presented later this year.

An analysis of a nationwide sample of more than 30,000 clinicians provides insight into rates of HPV vaccination among US adolescents and how changes in reimbursement rate might encourage increased vaccination rates.

A secondary analysis of ASPREE is bringing the role of aspirin in primary prevention settings further into question, suggesting daily use of low-dose aspirin was associated with a 38% increase in intracranial bleeding in older adults.

A study from Denmark leveraging more than 40 million years of follow-up data from patients dating back to the 1950s offers insight into the apparent increase in the risk of myocardial infarction associated with pregnancy loss in women and whether this same effect is observed in male partners.

The American Diabetes Association, together with the American Association of Clinical Chemistry, has released a new, 49-page document outlining optimized guidance for use of laboratory analysis in the diagnosis and management of diabetes.

Data from a phase 1, first-in-human trial of NI006 suggests the agent could have a potential role in the management of transthyretin amyloid cardiomyopathy.

A multipart, phase 1 trial provides evidence demonstrating the safety of zilebesiran, an RNA interference agent, which appeared to have a favorable safety profile among adult patients with hypertension.

New data presented at the 12th International AIDS Society Conference on HIV Science suggests use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events.

Leveraging data from a pair of commercial databases, a new study details the changes in febuxostat prescribing among patients with gout before, during, and after the FDA's addition of a Boxed Warning to prescribing information.

A single-center retrospective study is offering clinicians insight into the effects of biosimilar infliximab use on weight, height, and BMI trajectories in pediatric patients with inflammatory bowel disease.

A systematic review of 55 studies conducted in the US and abroad details the effects of private equity ownership in health care settings on costs to patients/payers as well as clinical outcomes.

A retrospective analysis of nearly 150 patients with gouty arthritis in China provides further insight into the relationship between pathological ultrasound features and clinical signs and symptoms among this patient population.

An analysis of EHR data recorded from 2018-2022 within Duke University Medical Center-affiliated diabetes care centers suggests the increased rate of new-onset type 1 and type 2 diabetes observed during the first year of the pandemic persisted through 2022.

Reaffirming their 2016 recommendation, the USPSTF concluded current evidence was insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents in their latest recommendation statement.

An analysis of patient data from the greater Houston area suggests women were less likely to be routed to a comprehensive stroke center than their male counterparts, despite a greater symptom severity and comparable distance to the centers.

Announced on July 17, 30-month data from the ATTRibute-CM trial provide the most comprehensive insight yet into the long-term effects of acoramidis use in patients with transthyretin amyloid cardiomyopathy.

A randomized trial of patients with kidney failure undergoing hemodialysis is underlining the importance of physical activity among this patient population.

An analysis of NHANES data is offering clinicians an overview of associations between hyperuricemia and gout with increased risk of mortality in patients with heart failure.

With the popularity of the class skyrocketing, the American Society of Anesthesiologists has released new guidance urging patients to withhold GLP-1 receptor agonist use prior to elective surgeries or procedures based on potential risk of regurgitation and aspiration associated with delayed gastric emptying.

A microsimulation model leveraging data from NHANES suggests monthly prescriptions of fruits and vegetables to people with diabetes and food insecurity could prevent nearly 300,000 cardiovascular disease events over a 25-year period.

Using data from more than 8500 patients from a bioimaging study, investigators took a deep dive into potential associations between gut microbiome and subclinical atherosclerosis in adults without a history of cardiovascular disease

Announced by Tandem Diabetes Care on July 11, 2023, the Tandem Mobi insulin pump is billed as the world's smallest insulin pump, at less than half the size of the t:slim X2 pump and able to fit in a coin pocket.

To celebrate the first half of 2023, we are recapping the top FDA approvals through June 2023 from within the HCPLive Network of brands.

Expansions in access by the Centers of Medicare and Medicaid Services could bring the latest advances in continuous glucose monitoring into the hands of millions with diabetes, which could provide significant, population-level impact and bring the field a step closer to equitable diabetes management.

Our endocrinology month in review for June 2023, highlights FDA decisions in type 1 and type 2 diabetes, studies from ENDO 2023, and new data presented at the 83rd Scientific Sessions of the American Diabetes Association.

An analysis of data from nearly 750,000 adolescents from more than 40 countries offers insight into the changing, and possibly inaccurate, perceptions of healthy body weight among younger people since the turn of the century.

A recap of the top news from the 83rd Scientific Sessions of the American Diabetes Association, including data related to retatrutide, tirzepatide, oral semaglutide, and more!